化痰解郁方对冠心病PCI术后焦虑抑郁的非劣效性研究

发布时间：2017-12-28 22:11

本文关键词：化痰解郁方对冠心病PCI术后焦虑抑郁的非劣效性研究　出处：《福建中医药大学》2016年硕士论文　论文类型：学位论文

更多相关文章： 化痰解郁方 冠心病 PCI 焦虑抑郁

【摘要】：目的：观察中药化痰解郁方对冠状动脉粥样硬化性心脏病(冠心病)经皮冠状动脉介入治疗(Percutaneous Coronary Intervention,PCI)术后合并焦虑抑郁患者的疗效,为临床治疗冠心病PCI术后合并焦虑抑郁提供一定的参考,提高患者生存质量。方法：选择福建中医药大学附属人民医院心内科住院及门诊冠心病PCI术后焦虑抑郁患者66例为研究对象,随机分为化痰解郁方组、黛力新组,在冠心病支架植入状态规范治疗的基础上分别加用中药化痰解郁方和西药黛力新。于治疗前后分别给予汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)、世界卫生组织生存质量测定简表(WHOQOL-BREF)进行评分。统计分析比较治疗前后组间及组内差异,并检验化痰解郁方对该病的疗效是否非劣于黛力新。结果：1、化痰解郁方组和黛力新组HAMA、HAMD积分治疗后较治疗前均有明显降低,组内对比差异有显著统计学意义P0.01)。2、治疗后两组在HAMA、HAMD积分上,差异无统计学意义(P0.05)。3、化痰解郁方组对焦虑抑郁临床有效率为93.55%,黛力新组临床有效率为96.88%,组间比较差异无统计学意义(P0.05)。4、化痰解郁方组和黛力新组WHOQOL-BREF4个领域积分治疗后较治疗前均有明显升高,组内对比差异有显著统计学意义(P0.01)。5、治疗后两组在WHOQOL-BREF积分,在生理领域、心理领域、社会关系领域上组间比较差异无统计学意义(P0.05)；在环境领域上组间比较差异有统计学意义(P0.05)。6、对化痰解郁方组和黛力新组治疗前后HAMA、HAMD积分进行非劣效性检验,化痰解郁方组非劣于黛力新组(P0.01)。结论：1、化痰解郁方能显著改善冠心病PCI术后患者焦虑抑郁症状,且疗效非劣于黛力新。2、化痰解郁方能显著提高冠心病PCI术后合并焦虑抑郁患者的生存质量。
[Abstract]:Objective: To observe the effect of Huatan Jieyu Decoction on coronary heart disease (CHD) after percutaneous coronary intervention (Percutaneous Coronary Intervention, PCI) patients with postoperative anxiety and depression, provide a reference for the clinical treatment of coronary heart disease patients after PCI combined with anxiety and depression, improve the quality of life of patients. Methods: Fujian University of TCM Affiliated Hospital Department of Cardiology inpatient and outpatient coronary heart disease patients after PCI in patients with anxiety and depression in 66 cases as the research object, randomly divided into Huatan Jieyu Decoction group, Deanxit group, on the basis of coronary heart disease stent implantation on the treatment of state specifications were added Jieyu Decoction and Western medicine Deanxit in phlegm medicine. Before and after treatment, Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD) and WHO quality of life (WHOQOL-BREF) were used to score. Statistical analysis before and after treatment were compared between group and group differences, and test the effect of Huatan Jieyu Decoction on the disease is not inferior to the new Daili. Results: 1, Huatan Jieyu Decoction group and control group HAMA, HAMD score after treatment were lower than before the treatment, there were significant differences in the comparison group) P0.01. 2. There was no significant difference in HAMA and HAMD scores between the two groups after treatment (P0.05). 3, Huatan Jieyu Decoction group was 93.55% for anxiety and depression in clinical, clinical Deanxit group was 96.88%, there was no significant difference between groups (P0.05). 4, Huatan Jieyu Decoction group and control group WHOQOL-BREF4 field score after treatment than before treatment were significantly increased, there was significant difference in the contrast group (P0.01). 5, after treatment, there was no significant difference in the WHOQOL-BREF score between the two groups in the field of physiology, psychology and social relations (P0.05). There was a significant difference between the two groups in the field of environment (P0.05). 6, the Huatan Jieyu Decoction group and control group before and after treatment HAMA, HAMD score for noninferiority, Huatan Jieyu Decoction group was not inferior to control group (P0.01). Conclusion: 1, Huatan Jieyu Decoction can significantly improve coronary heart disease patients after PCI symptoms of anxiety and depression, and the curative effect is not inferior to the new Daili. 2, Huatan Jie Yu Fang can significantly improve the quality of life of patients with anxiety and depression after coronary heart disease PCI.
【学位授予单位】：福建中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R541.4

【相似文献】